Is stem cell therapy safe?

The question of whether stem cell therapy is safe attracts conflicting answers. Some proponents describe any injection labeled "stem cells" as carrying the safety profile of the best-run clinical trials. Some critics describe every clinic outside the United States as operating without oversight. Neither characterization is accurate.

The underlying reality is variance. When researchers at the University of Minnesota and UC Davis surveyed the direct-to-consumer industry in 2016, they found hundreds of businesses in the United States alone marketing cell-based interventions, with enormous differences in what was actually being injected, by whom, and on what evidence.^[1] A companion analysis mapped the same pattern worldwide.^[2] Some providers use characterized, laboratory-tested mesenchymal stromal cells at defined doses. Others use unverified products of unknown cell count and identity. Both call it "stem cell therapy." The difference is not academic. In 2017, physicians reported in the New England Journal of Medicine that three patients suffered severe bilateral vision loss after receiving injections of an unverified adipose-derived cell product at a single United States clinic,^[8] and a 2018 review compiled the published reports of safety incidents associated with unproven stem cell interventions worldwide.^[9]

For this reason the question cannot be answered with a single yes or no about the field. It must be answered in layers: the safety record of the cell type itself in controlled trials, the regulatory framework the clinic operates under, and the release standards of the specific laboratory supplying the cells. Each layer can be verified, and the remainder of this article examines them in order.

The short version

In controlled trials, mesenchymal stromal cell therapy has a consistently reassuring short-term safety record: no meta-analysis has linked it to tumor formation, and the most common attributable effect is transient fever. The principal safety variable is not the cell type but the quality of the laboratory and the transparency of the clinic.

The best evidence on MSC safety comes from systematic reviews that pool every eligible randomized controlled trial and count adverse events. The first major one, the SafeCell analysis published in 2012, examined prospective clinical trials of intravascular MSC delivery across conditions from heart disease to Crohn's disease. It reported a significant association with transient fever, and no association with acute infusional toxicity, organ system complications, infection, death, or malignancy.^[3]

Because a 2012 snapshot could miss late-emerging harms, the same research group repeated the exercise in 2020 with roughly twice the number of trials and over 2,500 treated patients, including studies with years of follow-up. The conclusion held. MSC administration remained associated with fever and nothing more serious; malignancy rates in treated patients were no higher than in controls.^[4] The paper's title states its finding plainly: cell therapy with MSCs "continues to appear safe." Condition-specific analyses report the same pattern; a 2022 meta-analysis of 28 randomized trials in osteoarthritis, for example, found no significant difference in treatment-related adverse events between cell-treated patients and controls.^[11]

Across two decades of randomized trials, the most consistent adverse event attributable to MSC infusion is a transient fever, and no meta-analysis has found an association with tumor formation.

Three caveats apply. First, these analyses cover trial-grade cells that were characterized, tested, and dosed under protocol. They say nothing about an unverified product from an unaudited supplier, which is why the laboratory questions later in this article matter. Second, safety and efficacy are separate questions: a reassuring safety record does not establish effectiveness, and efficacy varies by condition. The condition-specific evidence is reviewed in the companion articles on arthritis and neuropathy. Third, every medical procedure carries procedural risk (injection-site pain, bruising, and the small infection risk associated with any needle), which is managed by clinical technique rather than by the cells.

It is sometimes asserted that stem cell treatment in Mexico occurs in a regulatory vacuum. This is not the case. Medical practice, cell banking, and the use of human tissue in Mexico are governed by the Ley General de Salud (General Health Law) and overseen by COFEPRIS, the Comisión Federal para la Protección contra Riesgos Sanitarios, Mexico's federal health-risk regulator and the counterpart to agencies such as the FDA.^[7]

Under this framework, several things require government licensing rather than mere registration. Establishments that procure, process, store, or dispose of human cells and tissues must hold a sanitary license and operate under a named, government-recognized responsible officer. Hospitals and clinics where procedures are performed carry their own establishment licenses. Physicians must hold a Mexican professional license (cédula profesional), with specialty credentials on top of it. These credentials are documents rather than claims; each one can be produced on request.

The practical difference between the Mexican and U.S. frameworks is not the presence or absence of oversight; it is that Mexican law gives licensed physicians wider latitude to use cell-based preparations in clinical practice, whereas the FDA restricts expanded (culture-grown) cells to registered trials. That latitude is the reason treatment is available in Mexico, and it is also the reason the burden of vetting shifts toward the individual clinic and laboratory. The regulator sets the floor; the clinic's own standards determine everything above it. A full comparison of the two frameworks appears in the companion article on US and Mexican regulation. TrueCell's own procedures take place in facilities that hold these licences. In Cancún, treatment is performed at Centro Quirúrgico Mayan in the KUN Building on Av. Bonampak, which holds COFEPRIS sanitary licence 22-AM-23-005-0002 for outpatient surgical procedures. In Tijuana, treatment is performed at Hospital Blue Medical Tower, a licensed private hospital in Zona Urbana Río. Either licence can be produced on request, and the numbers can be checked against the regulator's records. International bodies such as the ISSCR publish guidelines for what responsible clinical translation of stem cell science looks like anywhere in the world, and they are a fair yardstick to hold any provider against, in any country.^[6] The International Society for Cell & Gene Therapy has taken a parallel position, formally distinguishing evidence-based cell therapy from unproven commercial offerings that fall short of recognized standards of proof for safety and efficacy.^[10]

The safety literature in Section 02 describes characterized cells, so the operative question for any patient is whether the cells they would receive are characterized the same way. That work happens in the laboratory, before a physician ever draws the dose, and it produces a specific document: the certificate of analysis (COA) for the batch.

A complete COA states the cell count, the viability percentage at release, the passage number (the number of times the culture has been expanded; lower passages are preferred because extensively passaged cells decline in potency), the surface-marker results against the ISCT criteria,^[5] and the sterility, mycoplasma, and endotoxin results for the lot. It is tied to a batch number that matches the vial. A clinic that works with a serious laboratory can show you this document without hesitation, because it already uses it internally to accept or reject incoming batches.

For the cells TrueCell administers, that document exists for every batch. The cells are cultured by GenNova Stem Cells in México and released with a quality and traceability certificate that records the identity profile by flow cytometry (CD105, CD90 and CD73 positive; CD45 and CD34 negative), a karyotype confirming normal chromosomes after expansion, an expression screen for the oncogenes P53, C-MYC, C-MYB and KRAS against a control culture, sterility testing for bacteria and mycoplasma, and donor serology for hepatitis B, hepatitis C and HIV. Exosome batches carry a parallel certificate: tetraspanin markers CD9, CD63 and CD81, particle sizing by nanoparticle tracking, and transmission electron microscopy. Cells are supplied fresh rather than frozen, held at 4 to 8 °C, and used within hours of harvest. Patients receive the certificate for their own batch after treatment, tied to the lot number recorded in their file. The certificates themselves are not published here; they are shown to patients, not to the public.

Where the cells come from matters too, and it is covered in depth in the article on cell sourcing: umbilical-cord tissue from screened, consenting donors after healthy full-term births has become the standard source for allogeneic therapy, in part because it allows exactly this kind of bank-level testing and characterization before any patient is involved.

Everything above reduces to a short list of questions that any legitimate provider can answer with documents and specifics, in writing, before you pay anything. Ask them of every clinic you consider, ours included:

• Which laboratory supplies your cells, and can I see a certificate of analysis for a recent batch? You are looking for a named, licensed lab and a COA showing count, viability, passage number, marker profile, and sterility results.
• What exact cell type and dose would I receive, and by what route? A generic answer of "stem cells" is insufficient; an adequate answer specifies umbilical cord–derived mesenchymal stromal cells, a stated number of cells, and delivery intravenously or by image-guided injection. The protocols described on our treatments page are written in these terms so they can be compared and questioned.
• Who performs the procedure, and what is their license number? A Mexican physician's cédula profesional is verifiable through the federal registry. Board certifications have issuing bodies you can check.
• What licenses does the facility hold? Establishment and sanitary licenses exist on paper. A clinic operating inside an accredited hospital can also tell you which hospital and why.
• Will a physician review my records before quoting a protocol? A dose recommended before anyone has seen your history and imaging is a sales figure, not a clinical judgment.
• What should I not expect? This question is often the most informative. A candid provider will state the limits: which outcomes the evidence supports, which it does not, and who is not a candidate.

The warning signs are the inverse of this list: guaranteed results or the word "cure"; a single price and dose applied to every patient and condition; reluctance to name the laboratory; pressure to book before records are reviewed; and claims that a single treatment addresses a long list of unrelated diseases. None of these proves a clinic is dangerous, but each indicates that the burden of proof has not been met, which in medicine is sufficient reason to continue looking elsewhere.

Safety is ultimately not a property of a therapy in the abstract; it is a property of characterized cells, released by a tested process, administered by licensed practitioners to a patient whose candidacy has been evaluated. Each of those links can be verified before you commit, and a clinic worth choosing will welcome the questions.

Is stem cell therapy legal in Mexico?

Yes. The use of human cells and tissues in Mexico is governed by the Ley General de Salud and overseen by COFEPRIS, which licenses the establishments that process and store cells and the facilities where procedures take place. Legality is not the same as quality, however, so the licenses of the specific clinic and laboratory still need to be verified.

What are the most common side effects?

In pooled randomized trials of mesenchymal stromal cells, the most common adverse event attributable to the cells themselves is a transient fever, and meta-analyses have not found an association with tumor formation or organ complications. Procedural effects such as injection-site soreness and bruising also occur, as with any needle-based treatment. Long-term data continue to accumulate, so this record describes characterized, trial-grade cells rather than every product sold under the name.

Are the cells TrueCell uses tested before treatment?

Yes. Every batch from GenNova Stem Cells is released with a quality and traceability certificate covering surface-marker identity, karyotype, an oncogene expression screen, sterility for bacteria and mycoplasma, and donor serology for hepatitis B, hepatitis C and HIV. The lot number is recorded against each patient's procedure, and the patient receives the certificate for their batch after treatment.

Is the Cancún facility licensed?

Yes. Centro Quirúrgico Mayan, in the KUN Building on Av. Bonampak in downtown Cancún, holds COFEPRIS sanitary licence 22-AM-23-005-0002 for outpatient surgical procedures. Tijuana procedures take place at Hospital Blue Medical Tower, a licensed private hospital. Both documents can be shown on request.

How do I verify a clinic's laboratory?

Ask for the laboratory's name and sanitary license, and for a certificate of analysis tied to a recent batch number. The certificate should state cell count, viability, passage number, surface-marker results, and sterility testing. A clinic that cannot produce these documents has not met the burden of proof, whatever else it promises.